Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: A multicenter...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter M. Kotaka
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors M. Kotaka1, H. Satake2, Y. Okita2, Y. Hatachi2, T. Kotake2, H. Hashida3, T. Kato4, A. Tsuji2
  • 1Sano Hospital, Kobe-shi, Japan, /
  • 2Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan, /
  • 3Kobe City Medical Center General Hospital, Kobe, Japan, /
  • 4Kansai Rosai Hospital, Dept. of Surgery, Amagasaki, Japan, /

Abstract

Regorafenib (REG) and TAS-102 (TAS) have been approved as salvage treatment drugs for patients with metastatic colorectal cancer (mCRC) that progressed after standard chemotherapies. To date, however, no clinical comparison of these two drugs has been reported. The aim of this study was to compare the efficacy and safety of REG alone and TAS alone in patients with mCRC refractory to standard chemotherapies.